CTMX
CytomX Therapeutics, Inc.
Biotechnology · Healthcare · United States
2.34
close · 2026-10-30
value
57
cheaper than peers57
quality
33
stronger fundamentals33
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 1 year ago | 16.2% | 98 |
| earnings yield, 2 years ago | -0.4% | 86 |
| price to book | 1.69× | 77 |
| earnings yield, latest year | -6.4% | 60 |
| cash flow yield, 2 years ago | -11.2% | 45 |
| cash flow yield, latest year | -14.9% | 42 |
| cash flow yield, 1 year ago | -17.0% | 38 |
| price to sales | 27.86× | 31 |
| cash flow yield, 3 years ago | -22.1% | 28 |
| earnings yield, 3 years ago | -64.5% | 27 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.9% | 87 |
| return on equity | -37.8% | 62 |
| operating margin | -1677.1% | 15 |
| revenue growth | -92.4% | 3 |
4 of 4 measures available
Facts
| market cap | $510M |
| free cash flow | -$75.2M |
| employees | 69 |
| first trade | 2015-10-08 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.15 | 0.38 | -0.01 | -1.51 |
| free cash flow | -$75.8M | -$86.5M | -$56.9M | -$112.5M |
| net income | -$17.4M | $31.9M | -$569,000 | -$99.3M |
| revenue | $76.2M | $138.1M | $101.2M | $53.2M |